Bacillus Calmette-Guérin (has been the standard of care for bladder cancer for nearly 40 years. Little is known about BCG or its mechanism of action, however. A trial currently under way at M.D. Anderson Cancer Center, Houston, may help urologists to separate responders from nonresponders early and tailor therapy for optimal results in those who respond to the drug.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.